Drugs / EB-CARMSLN-NK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07598955 | Mar 2026 → Jun 2027 expected | thymic carcinoma, thymoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-CARMSLN-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07598955 ↗ |